Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10

Human Mutation

Volumn 32, Issue 1, 2011, Pages 51-58

  Frank Raue, Karin ^a   Rybicki, Lisa A ^b   Erlic, Zoran ^c   Schweizer, Heiko ^c   Winter, Aurelia ^c   Milos, Ioana ^c,d   Toledo, Sergio P A ^e   Toledo, Rodrigo A ^e   Tavares, Marcos R ^e   Alevizaki, Maria ^f   Mian, Caterina ^g   Siggelkow, Heide ^h   Hüfner, Michael ⁱ   Wohllk, Nelson ^j   Opocher, Giuseppe ^g   Dvořáková, Šárka ^k   Bendlova, Bela ^l   Czetwertynska, Małgorzata ^l   Skasko, Elzbieta ^l   Barontini, Marta ^m   Sanso, Gabriela ^m   Vorländer, Christian ⁿ   Maia, Ana Luiza ^o   Patocs, Attila ^p   Links, Thera P ^q   De Groot, Jan Willem ^q   Kerstens, Michiel N ^q   Valk, Gerlof D ^r   Miehle, Konstanze ^s   Musholt, Thomas J ^t   Biarnes, Josefina ^u   Damjanovic, Svetozar ^v   Muresan, Mihaela ^w   Wüster, Christian ^x   Fassnacht, Martin ^y   Peczkowska, Mariola ^z   Fauth, Christine ^aa   Golcher, Henriette ^ab   Walter, Martin A ^ac   Pichl, Josef ^ad   Raue, Friedhelm ^a   Eng, Charis ^b   Neumann, Hartmut P H ^c   more..

^a Endocrine Practice and Molecular Laboratory   (Germany)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

ⁱ Endokrinologikum   (Germany)

^j UNIVERSITY OF CHILE   (Chile)

^k INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^l INSTITUTE OF ONCOLOGY   (Poland)

^m HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

ⁿ Hospital de Niños R Gutiérrez ^*  (Germany)

^o FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^p SEMMELWEIS UNIVERSITY   (Hungary)

^q UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^r UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^s UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^t UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^u HOSPITAL JOSEP TRUETA   (Spain)

^v UNIVERSITY OF BELGRADE   (Serbia)

^w Bon Secours Hospital   (France)

^x Private Praxis for Endocrinology   (Germany)

^y UNIVERSITY OF WÜRZBURG   (Germany)

^z INSTITUTE OF CARDIOLOGY   (Poland)

^aa INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^ab UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^ac UNIVERSITY HOSPITAL BASEL   (Switzerland)

^ad StTheresien Hospital   (Germany)

more..

Author keywords

Genotype phenotype; Medullary thyroid carcinoma; MEN2; MEN2A; MEN2B; Pheochromocytoma; RET

Indexed keywords

PROTEIN RET;

ADULT; ARTICLE; CANCER STAGING; CODON; EXON; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GROUPS BY AGE; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PENETRANCE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CODON; EXONS; FEMALE; GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASM STAGING; PENETRANCE; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; YOUNG ADULT;

EID: 78650484357     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21385     Document Type: Article

References (32)

1. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G. 1998. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 83:3361-3364.
2. Borrego S, Ruiz A, Saez ME, Gimm O, Gao X, Lopez-Alonso M, Hernandez A, Wright FA, Antinolo G, Eng C. 2000. RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. J Med Genet 37:572-578.
3. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C. 1999. Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771-774.
4. Borrego S, Wright FA, Fernandez RM, Williams N, Lopez-Alonso M, Davuluri R, Antinolo G, Eng C. 2003. A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet 72:88-100.
5. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr SA, Marx SJ. 2001. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671.
6. Butter A, Gagne J, Al-Jazaeri A, Emran MA, Deal C, St-Vil D. 2007. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. J Pediatr Surg 42:203-206.
7. Calva D, O'Dorisio TM, Sue O'Dorisio M, Lal G, Sugg S, Weigel RJ, Howe JR. 2009. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation? Ann Surg Oncol 16:2237-2244.
8. DeLellis RA, Williams ED. 2004. Thyroid and parathyroid tumours. In: Lloyd RV, Heitz PU, Eng C, editors. World Healthe Organization Classifican of Tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press, pp 51-56.
9. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A. 2007. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92:4725-4729.
10. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thibodeau S, Lacroix A, Frilling A, Ponder B, Mulligan LM. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579.
11. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, Mussig K, Muresan M, Schaffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Plöckinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz MK, Eng C, Neumann HP, European-American Pheochromocytoma Study Group. 2009. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res 15:6378-6385.
12. Fernandez RM, Antinolo G, Eng C, Borrego S. 2003. The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Hum Mutat 22:412-415.
13. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W, Raue F. 2006. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155:229-236.
14. Greene LF PD, Fritz DA, Batch M, Haller DG, Morrow M. 2002. Cancer staging mannua. 6th ed. Chicago, IL: American Joint Committee on Cancer (AJCC).
15. Hansen HS, Torring H, Godballe C, Jager AC, Nielsen FC. 2000. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome? Cancer 89:863-867.
16. Iihara M, Yamashita T, Okamoto T, Kanbe M, Yamazaki K, Egawa S, Yamaguchi K, Obara T. 1997. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. Jpn J Clin Oncol 27:128-134.
17. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA 2009. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612.
18. Machens A, Hauptmann S, Dralle H. 2009. Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10. Endocr Relat Cancer 16:171-177.
19. Mian C, Barollo S, Zambonin L, Pennelli G, Bernante P, Pelizzo MR, Nacamulli D, Mantero F, Girelli ME, Opocher G. 2009. Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation. Fam Cancer 8:379-382.
20. Milos IN, Frank-Raue K, Wohllk N, Maia AL, Pusiol E, Patocs A, Robledo M, Biarnes J, Barontini M, Links TP, de Groot JW, Dvorakova S, Peczkowska M, Rybicki LA, Sullivan M, Raue F, Zosin I, Eng C, Neumann HP. 2008. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. Endocr Relat Cancer 15:1035-1041.
21. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I. 1998. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48:265-273.
22. Moers AM, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IA, Blijham GH, Hoppener JW, Vroom TM, van Amstel HK, Lips CJ. 1996. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101:635-641.
23. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peçzkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466.
24. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C, European-American Paraganglioma Study Group, 2004. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943-951.
25. Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B, Januszewicz A, Eng C. 2007. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 357:1311-1315.
26. Ponder BA, Finer N, Coffey R, Harmer CL, Maisey M, Ormerod MG, Pembrey ME, Ponder MA, Rosswick P, Shalet S. 1988a. Family screening in medullary thyroid carcinoma presenting without a family history. Q J Med 67:299-308.
27. Ponder BA, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple P, Easton DF. 1988b. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1:397-401.
28. Santoro M, Carlomagno F, Melillo RM, Billaud M, Vecchio G, Fusco A. 1999. Molecular mechanisms of RET activation in human neoplasia. J Endocrinol Invest 22:811-819.
29. Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Välimäki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, Neumann HP, European-American Paraganglioma Study Group, 2005. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294:2057-2463.
30. Siggelkow H, Melzer A, Nolte W, Karsten K, Hoppner W, Hufner M. 2001. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. Eur J Endocrinol 144:467-473.
31. Sobin LH WC. 2002. TNM classification of malignant tumours. 6th ed.Hoboken, NJ: Wiley.
32. Zbuk KM, Eng C. 2007. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7:35-45.